Atorvastatin
Atorvaliq, Atorvastatin, Caduet, Lipitor, Lypqozet (atorvastatin) is a small molecule pharmaceutical. Atorvastatin was first approved as Lipitor on 1996-12-17. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Atorvaliq, Lipitor (generic drugs available since 2011-11-30)
CombinationsCaduet (generic drugs available since 2011-11-30, discontinued: Liptruzet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amlodipine besylate
+
Atorvastatin calcium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CADUET | Pharmacia & Upjohn | N-021540 RX | 2004-01-30 | 11 products, RLD, RS |
Atorvastatin calcium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ATORVALIQ | CMP Pharma | N-213260 RX | 2023-02-01 | 1 products, RLD, RS |
| LIPITOR | Upjohn | N-020702 RX | 1996-12-17 | 4 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amlodipine and atorvastatin | NDA authorized generic | 2023-10-31 |
| amlodipine besylate and atorvastatin calcium | NDA authorized generic | 2023-10-31 |
| atorvastatin calcium | ANDA | 2024-02-09 |
| caduet | New Drug Application | 2023-08-30 |
| lipitor | New Drug Application | 2023-02-15 |
| lypqozet | ANDA | 2024-01-24 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
— C10AA05: Atorvastatin
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA05: Atorvastatin and ezetimibe
— C10BA08: Atorvastatin and omega-3 fatty acids
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX03: Atorvastatin and amlodipine
— C10BX06: Atorvastatin, acetylsalicylic acid and ramipril
— C10BX08: Atorvastatin and acetylsalicylic acid
— C10BX11: Atorvastatin, amlodipine and perindopril
— C10BX12: Atorvastatin, acetylsalicylic acid and perindopril
— C10BX15: Atorvastatin and perindopril
— C10BX18: Atorvastatin, amlodipine and ramipril
HCPCS
No data
Clinical
Clinical Trials
1072 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | 9 | 23 | 78 | 42 | 17 | 169 |
| Dyslipidemias | D050171 | HP_0003119 | — | 8 | 15 | 27 | 31 | 10 | 90 |
| Coronary artery disease | D003324 | — | I25.1 | — | 3 | 15 | 34 | 14 | 65 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 11 | 12 | 27 | 8 | 5 | 61 |
| Healthy volunteers/patients | — | — | — | 48 | 1 | — | 6 | 3 | 58 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | 8 | 10 | 18 | 12 | 48 |
| Hypertension | D006973 | EFO_0000537 | I10 | 6 | 4 | 7 | 20 | 7 | 43 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | 2 | 10 | 17 | 8 | 38 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | 2 | 10 | 16 | 10 | 38 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 2 | 1 | 6 | 13 | 7 | 29 |
Show 101 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 9 | 1 | — | — | 11 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 2 | 6 | — | 2 | 10 |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | 7 | — | 2 | 10 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 4 | 2 | — | 2 | 9 |
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | 8 | 7 | — | — | 8 |
| Neoplasms | D009369 | — | C80 | 2 | 3 | 2 | — | — | 6 |
| Hiv | D006678 | — | O98.7 | 1 | 2 | 1 | — | 1 | 5 |
| Subdural hematoma chronic | D020200 | — | — | — | 2 | 1 | — | 1 | 4 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | 1 | — | — | 4 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 2 | 1 | — | — | 4 |
Show 37 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 2 | — | — | 2 | 5 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | — | 2 | 5 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 3 | 2 | — | — | — | 4 |
| Percutaneous coronary intervention | D062645 | — | — | 1 | 1 | — | — | 2 | 3 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | 1 | — | — | 2 | 3 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 3 | — | — | — | 3 |
| Mucocutaneous lymph node syndrome | D009080 | EFO_0004246 | M30.3 | 2 | 2 | — | — | — | 3 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | 2 | 3 |
| Balloon angioplasty coronary | D015906 | EFO_0003951 | — | — | 2 | — | — | 1 | 3 |
| Pathologic constriction | D003251 | — | — | 1 | 1 | — | — | 1 | 2 |
Show 66 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 3 | — | — | — | 1 | 4 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | 1 | 2 |
| Hereditary nonpolyposis colorectal neoplasms | D003123 | EFO_0007354 | — | 1 | — | — | — | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | 1 | — | — | — | — | 1 |
| Hiv seronegativity | D018023 | — | — | 1 | — | — | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 2 | 2 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 2 | 2 |
| Asymptomatic diseases | D058070 | — | — | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Aneurysm | D000783 | HP_0002617 | I72.9 | — | — | — | — | 2 | 2 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | — | 2 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | — | 1 | 1 |
| Coronary occlusion | D054059 | — | I21 | — | — | — | — | 1 | 1 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | — | 1 | 1 |
| Intracranial embolism | D020766 | EFO_1000991 | I66 | — | — | — | — | 1 | 1 |
Show 20 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atorvastatin |
| INN | atorvastatin |
| Description | Atorvastatin is a dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases. It has a role as an environmental contaminant and a xenobiotic. It is an aromatic amide, a member of monofluorobenzenes, a statin (synthetic), a dihydroxy monocarboxylic acid and a member of pyrroles. It is functionally related to a heptanoic acid. It is a conjugate acid of an atorvastatin(1-). |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 134523-00-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1487 |
| ChEBI ID | 39548 |
| PubChem CID | 60823 |
| DrugBank | DB01076 |
| UNII ID | A0JWA85V8F (ChemIDplus, GSRS) |
Target
Agency Approved
HMGCR
HMGCR
Organism
Homo sapiens
Gene name
HMGCR
Gene synonyms
NCBI Gene ID
Protein name
3-hydroxy-3-methylglutaryl-Coenzyme A reductase
Protein synonyms
3-hydroxy-3-methylglutaryl CoA reductase (NADPH), HMG-CoA reductase, hydroxymethylglutaryl-CoA reductase
Uniprot ID
Mouse ortholog
Hmgcr (15357)
3-hydroxy-3-methylglutaryl-coenzyme A reductase (Q5U4I2)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Caduet – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Liptruzet – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lipitor – Viatris
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lipitor – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Atorvastatin
+
Amlodipine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Atorvastatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 45,169 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
109,843 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use